# Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

> **NCT02239926** · PHASE2,PHASE3 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 5 (actual)

## Conditions studied

- Diarrhea Predominant Irritable Bowel Syndrome

## Interventions

- **DRUG:** Ranolazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02239926
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Difficulty in enrolling subjects
- **Last updated:** 2016-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02239926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02239926, "Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02239926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*